Ridge Biotechnologies develops AI-driven enzyme and targeted drug design platforms that combine proprietary machine learning models with massive cell-free experimental datasets. Its initial product lines, NativeLink designer enzymes and ProTrigger AI-designed protease‑cleavable linkers, target improvements in antibody‑drug conjugates, ADC safety/targeting, and other bioconjugates. The company emerged from stealth and has announced an ADC therapeutic discovery collaboration with a leading ADC-focused biotech to apply its ProTrigger and NativeLink products. Ridge says it can generate up to orders-of-magnitude more sequence‑function data than conventional methods, enabling rapid enzyme and prodrug design and modular systems that improve manufacturability and therapeutic performance. The founding team and advisory board include academic and industry leaders in protein engineering, cell‑free systems, and bioconjugation, supporting plans to advance discovery programs toward a new class of enzyme-based therapeutics.

Total raised

$25M

Funding rounds

1

Latest round

Seed

Latest activity

Sep 2025